

Estimation of the probability of reinfection with COVID-19 coronavirus by the SEIRUS model

 Alexander Okhuese Victor

doi: <https://doi.org/10.1101/2020.04.02.20050930>

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

[Abstract](#)[Info/History](#)[Metrics](#)[Preview PDF](#)

Abstract

With sensitivity of the Polymerase Chain Reaction (PCR) test used to detect the presence of the virus in the human host, the global health community has been able to record a great number of recovered population. Therefore, in a bid to answer a burning question of reinfection in the recovered class, the model equations which exhibits the disease-free equilibrium (E_0) state for COVID-19 coronavirus was developed in this study and was discovered to both exist as well as satisfy the criteria for a locally or globally asymptotic stability with a basic reproductive number $R_0=0$ for and endemic situation. Hence, there is a chance of no secondary reinfections from the recovered population as the rate of incidence of the recovered population vanishes, that is, $B=0$. Furthermore, numerical simulations were carried to complement the analytical results in investigating the effect of the implementation of quarantine and observatory

procedures has on the projection of the further spread of the virus globally. Result shows that the proportion of infected population in the absence of curative vaccination will continue to grow globally meanwhile the recovery rate will continue slowly which therefore means that the ratio of infection to recovery rate will determine the death rate that is recorded globally and most significant for this study is the rate of reinfection by the recovered population which will decline to zero over time as the virus is cleared clinically from the system of the recovered class.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study part of a series of disease control research self-sponsored by the author without any external sponsorship or grants. However, access to funds can improve the quality of the series.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Copyright

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Tweets referencing this article:

COVID-19_arXiv

@COVID19arXiv

Title: Estimation of the probability of reinfection with COVID-19 coronavirus by the SEIRUS model. **Authors:** Victor, A. O.. <https://t.co/NzvmwLvXW2> <https://t.co/BfigqHt396>

07 Apr 2020

Outbreak Science

@outbreaksci

Contribute a rapid review or request one for "Estimation of the probability of reinfection with COVID-19 coronavirus by the SEIRUS m..." (<https://t.co/yN9L8kciVZ>). "Add" or "Request" w/DOI (10.1101/2020.04.02.20050930) at <https://t.co/RnurTL3DyM>

@outbreaks

07 Apr 2020

0 Comments

medrxiv

 Disqus' Privacy Policy

 Login ▾

 Recommend

 Tweet

 Share

Sort by Newest ▾



Start the discussion...

LOG IN WITH

OR SIGN UP WITH DISQUS 

Name

Be the first to comment.

 Subscribe  Add Disqus to your siteAdd DisqusAdd  Do Not Sell My Data

 Back to top

 Previous

Next 

Posted April 06, 2020.

 **Download PDF**

 Data/Code

 Email

 Share

 Citation Tools

Like 0

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Subject Area

Infectious Diseases (except HIV/AIDS) 

Subject Areas

All Articles

Addiction Medicine

Allergy and Immunology

Anesthesia

Cardiovascular Medicine

Dentistry and Oral Medicine

Dermatology

Emergency Medicine

Endocrinology (including Diabetes Mellitus and Metabolic Disease)

Epidemiology

Forensic Medicine

Gastroenterology

Genetic and Genomic Medicine

Geriatric Medicine

Health Economics

Health Informatics

Health Policy

Health Systems and Quality Improvement

Hematology

HIV/AIDS

Infectious Diseases (except HIV/AIDS)

Intensive Care and Critical Care Medicine

Medical Education

Medical Ethics

Nephrology

Neurology

Nursing

Nutrition

Obstetrics and Gynecology

Occupational and Environmental Health

Oncology

Ophthalmology

Orthopedics

Otolaryngology

Pain Medicine

Palliative Medicine

Pathology

Pediatrics

Pharmacology and Therapeutics

Primary Care Research

Psychiatry and Clinical Psychology
Public and Global Health
Radiology and Imaging
Rehabilitation Medicine and Physical Therapy
Respiratory Medicine
Rheumatology
Sexual and Reproductive Health
Sports Medicine
Surgery
Toxicology
Transplantation
Urology